61 related articles for article (PubMed ID: 18030051)
1. In-111 ibritumomab scintigraphy (planar and SPECT) and FDG PET/CT before Y-90 ibritumomab treatment in a patient with mantle cell lymphoma.
Jiménez-Bonilla JF; Quirce R; Banzo I; Martínez-Rodríguez I; Sainz-Esteban A; Barragán JE; López-Cordovilla JJ; Carril JM
Clin Nucl Med; 2007 Dec; 32(12):952-3. PubMed ID: 18030051
[TBL] [Abstract][Full Text] [Related]
2. B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience.
Ulaner GA; Colletti PM; Conti PS
Radiology; 2008 Mar; 246(3):895-902. PubMed ID: 18258810
[TBL] [Abstract][Full Text] [Related]
3. Does tumoral (111)In-ibritumomab accumulation correlate with therapeutic effect and outcome in relapsed or refractory low-grade B-cell lymphoma patients undergoing (90)Y-ibritumomab radioimmunotherapy?
Kaneko K; Choi I; Nakagawa M; Shinozaki K; Uike N
Eur Radiol; 2014 Dec; 24(12):3191-8. PubMed ID: 25117746
[TBL] [Abstract][Full Text] [Related]
4. Early evaluation of tumor response to
Kitajima K; Okada M; Kashiwagi T; Yoshihara K; Tokugawa T; Sawada A; Yoshihara S; Fujimori Y; Yamakado K
Eur Radiol; 2019 Jul; 29(7):3935-3944. PubMed ID: 30899979
[TBL] [Abstract][Full Text] [Related]
5. FDG PET CT assessment of treatment response after yttrium-90 ibritumomab tiuxetan radioimmunotherapy.
Joyce JM; Degirmenci B; Jacobs S; McCook B; Avril N
Clin Nucl Med; 2005 Aug; 30(8):564-8. PubMed ID: 16024958
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
Bodet-Milin C; Kraeber-Bodéré F; Dupas B; Morschhauser F; Gastinne T; Le Gouill S; Campion L; Harousseau JL; Wegener WA; Goldenberg DM; Huglo D
Haematologica; 2008 Mar; 93(3):390-7. PubMed ID: 18268287
[TBL] [Abstract][Full Text] [Related]
7. Estimation of yttrium-90 Zevalin tumor-absorbed dose in ocular adnexal lymphoma using quantitative indium-111 Zevalin radionuclide imaging.
Erwin WD; Esmaeli B
Nucl Med Commun; 2009 Sep; 30(9):681-6. PubMed ID: 19528874
[TBL] [Abstract][Full Text] [Related]
8. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy.
Jacobs SA; Vidnovic N; Joyce J; McCook B; Torok F; Avril N
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7146s-7150s. PubMed ID: 16203814
[TBL] [Abstract][Full Text] [Related]
9. Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma.
Assié K; Dieudonné A; Gardin I; Buvat I; Tilly H; Vera P
Cancer Biother Radiopharm; 2008 Feb; 23(1):53-64. PubMed ID: 18298329
[TBL] [Abstract][Full Text] [Related]
10. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
[TBL] [Abstract][Full Text] [Related]
11. Perspectives of molecular imaging and radioimmunotherapy in lymphoma.
Iagaru A; Goris ML; Gambhir SS
Radiol Clin North Am; 2008 Mar; 46(2):243-52, viii. PubMed ID: 18619379
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
13. Bilateral Renal Involvement in Mantle Cell Lymphoma on FDG PET/CT.
Mukherjee A; Agarwal KK; Gogia A; Bal C; Kumar R
Clin Nucl Med; 2016 Apr; 41(4):e206-7. PubMed ID: 26914553
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography in mantle cell lymphoma.
Brepoels L; Stroobants S; De Wever W; Dierickx D; Vandenberghe P; Thomas J; Mortelmans L; Verhoef G; De Wolf-Peeters C
Leuk Lymphoma; 2008 Sep; 49(9):1693-701. PubMed ID: 18798104
[TBL] [Abstract][Full Text] [Related]
15. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
16. The standardized uptake value calculated from
Kume A; Toriihara A; Shimizu R; Harata N; Isogai J; Tanaka H
J Clin Exp Hematop; 2021 Mar; 61(1):29-34. PubMed ID: 33551439
[No Abstract] [Full Text] [Related]
17. Heterogeneity of intratumoral (111)In-ibritumomab tiuxetan and (18)F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
Hanaoka K; Hosono M; Tatsumi Y; Ishii K; Im SW; Tsuchiya N; Sakaguchi K; Matsumura I
EJNMMI Res; 2015; 5():10. PubMed ID: 25853016
[TBL] [Abstract][Full Text] [Related]
18. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
[TBL] [Abstract][Full Text] [Related]
19. Dynamic metabolic changes during the first 3 months after 90Y-ibritumomab tiuxetan radioimmunotherapy.
Takahashi M; Momose T; Koyama K; Ichikawa M; Kurokawa M; Ohtomo K
ScientificWorldJournal; 2014; 2014():368947. PubMed ID: 25050390
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
